Based on results showing that the bi-specific antibody CD30/CD16A (AFM13) can enhance NK cell cytotoxicity against CD30+ HL cells, this BiKE is currently under evaluation in a clinical study (NCT01221571, phase I) to assess its safety in HL patients [225,227,228,229,230]. Here, TNFRSF8 is linked to Hodgkins lymphoma.